血管生成因子在胎盘功能障碍妊娠中临床应用的现实世界数据
该现实世界数据分析纳入283例单胎妊娠,检测血清sFlt-1与PlGF比值。入院时比值正常者占58.7%,中间者19.1%,病理者22.3%。比值升高与分娩优先级增加相关(r=0.38;P<.001),病理组子痫前期发生率达49.2%,比值与分娩孕周、出生体重及延长妊娠时间呈负相关。
要点
- sFlt-1/PlGF比值可分层正常与胎盘功能障碍妊娠。
- 比值升高与分娩优先级增加、子痫前期风险增高相关。
- 比值与分娩孕周、出生体重及延长妊娠时间负相关。
核心结论
- sFlt-1/PlGF比值与胎盘功能障碍严重程度正相关,与分娩时间负相关。
研究设计与样本
- 现实世界数据分析,纳入283例未选择的单胎妊娠,至少检测一次sFlt-1/PlGF比值。
主要发现
- 入院时比值正常(<38)占58.7%,中间(38-85/110)占19.1%,病理(>85/110)占22.3%。
- 子痫前期或HELLP综合征占15.5%,宫内生长受限占15.5%。
- 比值升高与分娩优先级增加相关(r=0.38;P<.001)。
- 入院至分娩比值最大差值出现在病理妊娠(171.12 vs 正常妊娠39.84)。
- 比值与分娩孕周、出生体重及延长妊娠时间呈负相关。
关键数值与推荐
- 按入院sFlt-1/PlGF比值分层,子痫前期发生率分别为正常5.4%、中间7.4%、病理49.2%。
临床怎么用
- 临床可检测sFlt-1/PlGF比值辅助预测和诊断子痫前期及胎盘功能障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In routine clinical practice, angiogenic factor measurement can facilitate prediction and diagnosis of preeclampsia and other manifestations of placental dysfunction (eg, intrauterine growth restriction). OBJECTIVE: This real-world data analysis investigated the utility of soluble fms-like tyrosine kinase-1 and placental growth factor for preeclampsia and placental dysfunction. STUDY DESIGN: Blood serum soluble fms-like tyrosine kinase-1 and placental growth factor were measured using Elecsys soluble fms-like tyrosine kinase-1 and placental growth factor immunoassays (cobas e analyzer; Roche Diagnostics). Overall, 283 unselected singleton pregnancies with ≥1 determination of soluble fms-like tyrosine kinase-1-to-placental growth factor ratio were included. Distribution of the ratio at admission was normal (<38 [58.7%]), intermediate (38-85/110 [19.1%]), or pathologic (>85/110 [22.3%]). Overall, 15.5% had preeclampsia or hemolysis, elevated liver enzyme levels, and low platelet count, and 15.5% of women had intrauterine growth restriction. RESULTS: Increasing soluble fms-like tyrosine kinase-1-to-placental growth factor ratio was associated with an increase in priority of delivery (r=0.38; P<.001). The percentage of patients who developed preeclampsia by soluble fms-like tyrosine kinase-1-to-placental growth factor ratio at admission was 5.4% (normal), 7.4% (intermediate), and 49.2% (pathologic). The greatest difference in soluble fms-like tyrosine kinase-1-to-placental growth factor ratio from admission to birth occurred in pathologic pregnancies (171.12 vs 39.84 for normal pregnancies). Soluble fms-like tyrosine kinase-1-to-placental growth factor ratio correlated inversely with gestational age at delivery, birthweight, and prolongation time. There was no significant relation between the prolongation period or the gestational age at first determination to the increase of soluble fms-like tyrosine kinase-1 and placental growth factor between admission and delivery (ΔQ). This analysis used a real-world approach to investigate the clinical utility of the soluble fms-like tyrosine kinase-1-to-placental growth factor ratio in placental dysfunction. CONCLUSIONS: Confirming the results of prospective studies, we observed a positive correlation between soluble fms-like tyrosine kinase-1-to-placental growth factor ratio and severity of placental dysfunction and a negative association with time to delivery. In a real-world setting, the soluble fms-like tyrosine kinase-1-placental growth factor ratio stratifies patients with normal outcome and outcome complicated by placental dysfunction.
引用
- Dathan-Stumpf A, Czarnowsky V, Hein V, et al. Real-world data on the clinical use of angiogenic factors in pregnancies with placental dysfunction. Am J Obstet Gynecol. 2021. PMID: 33892922. doi:10.1016/j.ajog.2020.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。